Jubilant Ingrevia specialty chemicals strategy worth ₹2,000 crore shows results amid CDMO, nutrition growth.

Jubilant Ingrevia, part of the Jubilant Bhartia Group, is beginning to see early returns from its nearly ₹2,000-crore investment programme in specialty chemicals, contract development and manufacturing (CDMO), and nutrition ingredients, as it deepens its shift away from cyclical commodity chemicals toward higher-margin global specialty businesses.

The company said it has deployed over ₹2,000 crore over the past two years toward new manufacturing facilities, technology upgrades and expanded specialty capabilities. This includes investments in agro-CDMO operations, semiconductor chemistry infrastructure and multi-purpose specialty chemical plants.

According to the management, the investment cycle is set to continue into FY27, with further expansion of the multi-purpose plant at Gajraula, scaling up of semiconductor-focused R&D infrastructure, and continued deployment in advanced technologies such as flow chemistry and cryogenic systems.

The company’s strategy reflects a broader industry trend of chemical manufacturers moving toward specialty and innovation-led businesses to improve margins and reduce exposure to commodity price volatility.